Companies: 10,795·Total market cap: $144.5T
Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNLNASDAQHealthcare
$8.50
+$0.01(+0.12%)
Market Cap$27621005
P/E Ratio—
52W High$8.5
52W Low$3.1
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Liminal BioSciences Inc. (LMNL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · LMNL · as of Jun 9, 2026

Key Statistics

EPS (TTM)$4.18lmnl eps ttm · lmnl earnings per shareEarnings history
PE Ratio (TTM)2.0×lmnl pe ratio ttm · lmnl price to earningsPE Ratio deep dive
Revenue (TTM)492000.00lmnl revenue ttm · lmnl annual revenueFull revenue history
Dividend YieldNo Dividenddoes lmnl pay dividends · lmnl dividend yieldDividend history
Shares Outstanding84,600lmnl shares outstanding · lmnl floatShares outstanding history
Next EarningsTBAlmnl earnings date · lmnl next earningsEarnings history

Explore Liminal BioSciences Inc. Data

lmnl stock data · financials
Market Cap$27.6Mlmnl market cap · lmnl valuation
Analyst Forecast$— · Hold
DividendsNo Dividenddoes liminal biosciences inc. pay dividends · lmnl dividend yield
Revenue$401000-37.64%liminal biosciences inc. annual revenue · lmnl revenue
EarningsEPS $-341.80+35.83%lmnl earnings · lmnl eps
PE Ratio2.0×lmnl pe ratio · lmnl price to earnings

Financial Snapshot

Full Financials
FY 2022Revenue$401000.00▼ 37.64% YoY
202020212022
liminal biosciences inc. revenue · lmnl revenue 2022
FY 2022Net Income-$28.9M▲ +35.83% YoY
202020212022
liminal biosciences inc. net income · lmnl profit 2022
FY 2022EPS$-341.80▲ +35.83% YoY
202020212022
lmnl eps · liminal biosciences inc. earnings per share 2022
TTM:Revenue: $492000.00Net Income: $354000.00EPS: $4.18View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Hold2 analystsis lmnl a buy · lmnl analyst rating
Strong Buy
0
Buy
0
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$—Low
$8.50Current
$—Avg Target
$—High
lmnl price target · lmnl 12 month forecast

Total: 2 · Buy rate: 0.0%

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.00%
3M+1.67%
YTD+157.58%
1Y+67.32%
5Y-99.77%

About Liminal BioSciences Inc.

CEOBruce Pritchard BA, CA, FIOD
IPO DateDec 18, 2009
Employees251
CountryCA
Websiteliminalbiosciences.com

Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammator…

BiotechnologyHealthcareNASDAQCA

what is liminal biosciences inc. · lmnl stock overview · liminal biosciences inc. company profile · who is liminal biosciences inc. ceo · lmnl NASDAQ · liminal biosciences inc. headquarters · liminal biosciences inc. business segments

About Stock Overview & Key Data

Liminal BioSciences Inc. (LMNL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 18, 2009. As of the latest trading session, LMNL stock price is $8.50, with a market capitalization of $27.6M. The stock has returned +67.32% over the past 12 months and +157.58% year-to-date.

According to 2 Wall Street analysts, the consensus rating for Liminal BioSciences Inc. stock is Hold, with an average 12-month price target of $—. In fiscal year 2022, Liminal BioSciences Inc. reported revenue of $401000.00 and net income of -$28.9M. For detailed data — including Liminal BioSciences Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Liminal BioSciences Inc. (LMNL) stock price is $8.50. The stock is traded on NASDAQ under the ticker symbol LMNL. The 52-week range is $3.10 – $8.50.

LMNL stock priceLMNL quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice